WFH/LinkedIn
Sep 18, 2025, 09:18
WFH Vice President Glenn Pierce on Slow Uptake and Industry Shifts in Hemophilia Gene Therapy
The World Federation of Hemophilia (WFH) posted on LinkedIn:
”WFH Vice President, Medical, Glenn Pierce, joins Zoey Becker in this week’s episode of The Top Line, to unpack the complex reality of Gene Therapy for hemophilia. Pierce discusses why the uptake remains slow, what led to some pharma companies exit and who risks being left behind in this evolving landscape.
Listen now.”
Stay updated with Hemostasis Today.
-
Aug 21, 2026, 12:57David McIntosh: Why Do Blood Supplies Still Fall Short?
-
Aug 21, 2026, 12:48Joshua Penrod: 35 Years of Progress in Plasma Safety
-
Aug 21, 2026, 12:42Moustafa Abdou: Diagnosis and Management of Pyruvate Kinase Deficiency
-
Aug 21, 2026, 12:38Luluva Ghadiyali: Modern Approaches to Aplastic Anemia
-
Aug 21, 2026, 12:34Kellie Machlus: Animal Models Driving Progress in Thrombosis Research
-
Aug 21, 2026, 12:08Amy Allen Whitfield: Helping to Proceed Bleeding Disorders Care
-
Aug 21, 2026, 11:53Jan Terje Andersen: Harnessing Placental Biology for Therapeutic Engineering
-
Aug 21, 2026, 11:02Severe ITP, Critical Bleeding, and the Challenge of Platelet Testing – RPTH Journal
-
Aug 21, 2026, 10:46Arwa Z. Al-Riyami: Looking Ahead to ISBT Muscat 2029